Aspirin delimits platelet life span by proteasomal inhibition by Nayak, Manasa K. et al.
Aspirin Delimits Platelet Life Span by Proteasomal
Inhibition
Manasa K. Nayak1¤, Ayusman Dash2, Nitesh Singh1, Debabrata Dash1*
1Department of Biochemistry, Institute of Medical Sciences, Banaras Hindu University, Varanasi, India, 2 Indian Institute of Science Education and Research, Kolkata, India
Abstract
Aspirin is widely used in clinical settings as an anti-inflammatory and anti-platelet drug due its inhibitory effect on
cyclooxygenase activity. Although the drug has long been considered to be an effective and safe therapeutic regime against
inflammatory and cardiovascular disorders, consequences of its cyclooxygenase-independent attributes on platelets, the
key players in thrombogenesis, beg serious investigation. In this report we explored the effect of aspirin on platelet lifespan
in murine model and its possible cytotoxicity against human platelets in vitro. Aspirin administration in mice led to
significant reduction in half-life of circulating platelets, indicative of enhanced rate of platelet clearance. Aspirin-treated
human platelets were found to be phagocytosed more efficiently by macrophages, associated with attenuation in platelet
proteasomal activity and upregulation of conformationally active Bax, which were consistent with enhanced platelet
apoptosis. Although the dosage of aspirin administered in mice was higher than the therapeutic regimen against
cardiovascular events, it is comparable with the recommended anti-inflammatory prescription. Thus, above observations
provide cautionary framework to critically re-evaluate prophylactic and therapeutic dosage regime of aspirin in systemic
inflammatory as well as cardiovascular ailments.
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Introduction
Although aspirin has been widely used therapeutically against
variety of inflammatory conditions since 1890s [1], its anti-platelet
activity was not documented until almost 70 years later [2]. The
central role of platelets in pathogenesis of occlusive coronary and
cerebral thrombotic events has prompted in-depth investigations
into molecular underpinnings of aspirin action. Platelets generate
thromboxane A2 (TXA2) in response to diverse physiological
stimuli like collagen, thrombin and ADP that cause amplification
of platelet aggregation and vasoconstriction [3,4]. Aspirin and
other non-steroidal anti-inflammatory drugs (NSAIDs) effectively
attenuate activity of the enzyme cyclooxygenase-1 (COX-1), which
catalyzes biosynthesis of cyclic prostanoids like TXA2, prostacyclin
and other prostaglandins (PG) [5]. Although this accounts for
strong anti-thrombotic potential of aspirin, inhibition of prosta-
glandin synthesis, too, results in altered functions of normally
protective prostaglandins with potentially serious consequences.
Aspirin-induced inhibition of COX results in loss of cytoprotective
effects of PGE2 on gastric mucosa, which partly accounts for
gastrointestinal side effects associated with aspirin therapy [5–8],
especially during high dosage of aspirin administered for treatment
of systemic inflammatory ailments including rheumatoid arthritis
[9].
Aspirin also elicits effects that are independent of COX
inhibition [10–17]. Prolonged use of NSAIDs has been reported
to reduce the risk of malignancies, though their anti-cancer activity
has not been fully established [18–22]. Aspirin induces shedding of
GPIba and GPV from platelet surface through activation of the
metalloproteinase ADAM17 and cell death [23,24]. Clinical trials
have indicated that chemopreventive properties of NSAIDs could
be due to induction of apoptosis [6–8]. Several mechanisms have
been proposed to explain aspirin-induced apoptosis, which include
upregulation of pro-apoptotic proteins [7,8,25,26] and oxidative
stress [27,28]. Aspirin has been shown to induce decrement in
mitochondrial transmembrane potential and stimulate intrinsic
pathway of apoptosis in mouse Neuro 2a cells [29]. There have
been few clinical studies to suggest decrease in platelet count in
individuals under aspirin medication [30–32]. Although aspirin
has long been considered to be an effective and safe therapeutic
regime against cardiovascular disorders, consequences of its pro-
apoptotic attributes on platelets, the key players in thrombogen-
esis, demand serous investigation.
Proteasome, the protein degradation machinery of the cell,
cleaves intracellular proteins in order to regulate essential cellular
processes like antigen processing, cell cycle, transcription and
signal transduction [33–36]. We have recently demonstrated a
central role of proteasome in determination of platelet life span
[37] and the factors regulating its enzymatic activity in human
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platelets [38]. In the present study, we have evaluated effect of
aspirin on platelet survival in murine as well as human models.
Aspirin induced apoptosis in human platelets in a dose-dependent
manner, which was associated with concomitant inhibition of
platelet proteasomal activity in presence of the drug. Platelet half
life was found to be significantly lowered in aspirin-treated mice as
compared to control animals. Thus, above observations provide
cautionary framework to critically re-evaluate prophylactic and
therapeutic dosage regime of aspirin in clinical practice. Despite
widespread use of aspirin against cardiovascular ailments, its
preventive administration in susceptible individuals on routine
basis is not recommended [39–41]. Aspirin has been reported to
be safe for primary prevention at coronary event risk .1.5%/year
though it is not recommended due to associated side effects at
coronary event risk 0.5%/year [42]. In standard doses (325 mg)
aspirin poses less threat of gastrointestinal bleeding; however, the
bleeding risk is still twice as high as without aspirin [43].
Ethics Statement
The animal study was approved by the Central Animal Ethical
Committee of Institute of Medical Sciences, Banaras Hindu
University, Varanasi. Swiss Albino mice weighing between 18 and
20 gm (20 control and 40 aspirin-treated) were used in the entire
study. All efforts were made to minimize the number of animals
used and their suffering.
Materials and Methods
ABT-737 was purchased from Selleck Chemicals. Anti-CD61-
PE and annexin V-PE were from BD Pharmingen. Proteasome
inhibitor PSI [Z-Ile-Glu(OtBu)-Ala-Leu-CHO] procured from
Calbiochem. N-hydroxysuccinimidobiotin (NHS-biotin), PE-stre-
patvidin, 5,59-6,69-tetrachloro-1,19,3,39 tetraethylbenzimidazolyl-
carbocyanine iodide (JC-1), thiazole orange, carbonyl cyanide 3-
chlorophenylhydrazone (CCCP), 6-carboxy-29,79- dichlorodihy-
drofluorescein (H2DCFDA), acetyl-Asp-Glu-Val-Asp-7-amido-4-
methylcoumarin (AC-DEVD-AMC), apyrase, ethylene glycol tetra
acetic acid (EGTA), ethylene diamine tetra acetic acid (EDTA),
sodium orthovanadate, acetylsalicylic acid (aspirin), bovine serum
albumin (fraction V), Triton X-100, protease inhibitors, mouse
monoclonal anti-Bax (6A7) were purchased from Sigma. RPMI
1640 was purchased from HiMedia. Reagents for electrophoresis
were products of Merck. PVDF membranes were from Millipore.
SuperSignal West Pico chemiluminescent substrate was from
Pierce. Horseradish peroxidase (HRP)-labeled secondary antibod-
ies were purchased from Transduction Laboratories and Banga-
lore Genei, respectively. All other reagents were of analytical
grade. Type 1 deionized water (18.2 MV.cm, Millipore) was used
for preparation of solutions.
Platelet preparation
Platelets were isolated from fresh human blood by differential
centrifugation, as already described [44]. Briefly, blood was
collected from healthy volunteers (majority male) under informed
consent and centrifuged at 1806g for 10 min. PRP (platelet-rich
plasma) thus obtained was incubated with 1 mM acetylsalicylic
acid for 15 min at 37uC. After addition of EDTA (ethylenedi-
aminetetraacetic acid) (5 mM), platelets were sedimented by
centrifugation at 8006g for 15 min. Cells were washed in buffer
A (20 mM HEPES, 138 mM NaCl, 2.9 mM KCl, 1 mM MgCl2,
0.36 mM NaH2PO4, 1 mM EGTA (ethylene glycol tetraacetic
acid), supplemented with 5 mM glucose and 0.6 ADPase units of
apyrase/ml, pH 6.2) and were finally resuspended in buffer B
(20 mM HEPES, 138 mM NaCl, 2.9 mM KCl, 1 mM MgCl2,
0.36 mM NaH2PO4, pH 7.4). The final cell count was adjusted to
0.52.86109/ml. All steps were carried out under sterile conditions
and precautions were taken to maintain the cells in resting
condition.
Proteasome activity assay
Platelets were incubated at 37uC for 30 min with aspirin (2, 5
and 10 mM) or vehicle (ethanol) and washed twice in buffer A (see
above). Cells were pelleted and resuspended in 125 ml of 26
permeabilization buffer (20 mM HEPES, 0.2% Triton X-100,
300 mM NaCl and 2 mM EGTA, pH 7.7) followed by addition of
125 ml of 26 proteasome assay buffer (40 mM HEPES, 1 mM
EDTA and 0.07% SDS, pH 7.8). Permeabilized cells were added
to the wells of microplates in a fluorescence microplate reader
(BioTek model FLx800) at 37uC. Reaction was started by the
addition of Suc-Leu-Leu-Val-Tyr-AMC (25 mM) in DMSO and
was monitored for 10 min (excitation, 360 nm; emission, 460 nm)
[37]. Proteasome peptidase activities were determined from Suc-
LLVY-AMC-hydrolyzing activity (chymotrypsin-like activity).
Cytofluorimetric analysis of mitochondrial
transmembrane potential
Mitochondrial transmembrane potential (Dy) was measured
using the potential-sensitive fluorochrome JC-1, which selectively
moves across polarized mitochondrial membrane and forms
aggregates (red). As membrane potential collapses, color changes
from red to green due to release of monomeric dye [37]. In order
to study Dy, platelets were pre-treated with aspirin (2, 5 and
10 mM) or ethanol (vehicle) for 30 min, followed by incubation
with 2 mM JC-1 for 15 min at 37u C in dark. Cells were washed in
phosphate-buffered saline (PBS) and JC-1 fluorescence was
analyzed in FL1 and FL2 channels of flow cytometer (FACSCa-
libur, Becton Dickinson) for detection of dye monomer and
aggregates, respectively. The ratio of red to green (FL2/FL1)
fluorescence reflected mitochondrial transmembrane potential.
Flow cytometric measurement of reactive oxygen species
(ROS)
Platelets were treated with aspirin (2, 5 and 10 mM) or ethanol
(vehicle) as above, washed with PBS and incubated with
H2DCFDA (1 mM) for 30 min at 37uC in dark. Cells were next
washed twice with PBS and analyzed by flow cytometry as
described previously [45].
Measurement of annexin v and P-selectin binding by
flow cytometry
Platelets (16108 cells in 100 ml) were incubated at 37uC for
30 min in the presence aspirin or vehicle as stated above. For
positive control the washed platelets were treated with thrombin (1
U/ml) for 10 min without stirring. Then equal amount of 4%
paraformaldehyde was added to the cells and incubated for
30 min, which was followed by washing. Post-fixed resuspended
platelets were labeled with 5 ml FITC-labeled P-selectin antibody,
5 ml PE-labeled anti-CD61 antibody and 10 ml FITC-labeled
annexin V (in preseance of 5 mM CaCl2 to promote binding).
Samples were incubated for 30 min at RT in dark and analyzed
on the flow cytometer [45]. After compensation between FITC
and PE, all fluorescence data were collected using four-quadrant
logarithmic amplification. Data from CD61-positive 10,000 events
were collected for each sample.
Caspase-3 activity assay
To determine cytosolic caspase-3 activity, samples were pre-
treated with 2, 5 and 10 mM of aspirin or vehicle (ethanol) and
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lysed with equal amount of 26 RIPA buffer. After 10 min
incubation in ice, equal volume of 26 substrate buffer (20 mM
HEPES, pH 7.4, 2 mM EDTA, 0.1% CHAPS, 5 mM DTT and
10 mM caspase substrate AC-DEVD-AMC) was added to each
lysate and further incubated for 30 min at 37uC [45]. Caspase-3
activity was determined from the extent of cleavage of fluorogenic
substrate measured at 460 nm emission (excitation, 360 nm).
Western blotting
Proteins were separated by 13% SDS-PAGE and electropho-
retically transferred onto PVDF membrane (0.8 mA/cm2, 2 h) in
a semi-dry blotter (TE 77 PWR, GE Healthcare) for subsequent
probing as described previously [37]. Blots were incubated for 1 hr
with 5% (w/v) BSA in Tris-buffered saline containing 0.05%
Tween 20 (TBST) to block residual protein binding sites.
Membranes were incubated overnight at 4uC with the primary
antibody (anti-Bax, 1:500). Blots were incubated with the
appropriate HRP-conjugated secondary antibody (diluted
1:10,000) and exposed to enhanced chemiluminescence reagents
for 5 min. Blots were exposed to photographic films and
densitometrically scanned. For protein loading control, mem-
branes containing whole cell lysates were reprobed with the anti-
actin antibody (1:1000).
Platelet clearance analysis
Mice were orally administered with aspirin (10 and 15 mg/kg/
day, respectively, in two groups) for 4 days. The control animals
were administered with vehicle. In different experiments mice
were intravenously injected with 50 and 75 mg/kg of aspirin.
NHS-biotin (600 mg) was injected in tail vein of either ethanol
(control) or aspirin administered mice [46]. At various time points
50 ml retro-orbital blood was drawn from both control as well as
treated mice, mixed with 200 ml buffered saline-glucose-citrate
buffer (116 mM NaCl, 13.6 mM trisodium citrate, 8.6 mM
Na2HPO4, 1.6 mM KH2PO4, 0.9 mM EDTA, 11.1 mM glucose)
and followed by 1 ml balanced salt solution (149 mM NaCl,
3.7 mM KCl, 2.5 mM CaCl2, 1.2 mM MgSO4, 7.4 mM HEPES,
1.2 mM KH2PO4, 0.8 mM K2HPO4, 3% bovine calf serum).
Cells were pelleted at 14006g for 10 min, and resuspended in
300 ml sheath fluid. They were stained with FITC-conjugated rat
anti-CD41, which label only platelets, followed by PE-streptavidin
for 1 h on ice, washed in balanced salt solution and analyzed by
flow cytometry to determine the fraction of platelet population
labeled with PE.
Monocyte isolation, culture and phagocytic recognition
of platelets
Human monocytes were isolated and cultured as described
[47,48]. Briefly, blood from healthy donors was collected in citrate
and peripheral blood mononuclear cells (PBMCs) were isolated
using Hysep, according to manufacturer’s instructions. Monocytes
were further isolated by plating the PBMCs on polystyrene-coated
tissue culture flasks for 4 h at 37uC, followed by 3 washes with PBS
to remove non-adherent lymphocytes. Monocytes (250,000 in
500 ml volume) were then plated on 6-well plates in RPMI 1640
supplemented with 10% fetal bovine serum and cultured for 7
days to obtain the monocyte-derived macrophages (MDMs).
Platelets labeled with calcein-AM were incubated with a mono-
layer of autologous monocyte-derived adherent human macro-
phages for 45 min. Following incubation period, the phagocyte
monolayer was washed free of non-interacting platelets, and any
adherent platelets were removed by treatment with trypsin at 37uC
for 5 min followed by 5 mM EDTA at 4uC. MDMs were
recovered by trypsin/EDTA treatment for 15 min at 37uC and
subjected to flow cytometric and epifluorescent microscopic
analysis.
In different experiments, aspirin (10 mg/kg/day) was adminis-
tered orally to mice for 7 days, following which macrophages were
isolated from the peritoneal cavity of animals. Platelets were
isolated from control as well as aspirin-administered mice and
stained with calcein-AM. Equal number of platelets from either
group was co-incubated ex vivo with respective pre-isolated
macrophages for 45 min in CO2 incubator. Macrophages were
gated and analyzed by flow cytometry for fluorescence signal
(FL1).
Statistical methods
Standard statistical methods were used. Parametric methods (t
test) were used for evaluation and tests were considered significant
at P,0.05 (2-tailed tests). Data are presented as means 6 SD of at
least five individual experiments from different blood donors.
Results
Aspirin induces apoptosis-like phenotype in human
platelets associated with upregulation of Bax and
proteasomal inhibition
NSAIDs have been reported to induce apoptosis presumably
independent of their ability to inhibit cyclooxygenase activity [5–
8]. In order to evaluate aspirin action on platelets, we investigated
mitochondrial transmembrane potential (Dym) and surface expo-
sure of phosphatidylserine (PS) in aspirin-treated human platelets.
JC-1, a lipophilic cation, was employed to determine alterations in
Dym. As expected, high aggregate to monomer fluorescence ratio
(FL2/FL1) of the fluor was observed in untreated (control) cells
indicative of stabilized Dym, which dropped drastically in carbonyl
cyanide 3-chlorophenylhydrazone (CCCP) (protonophore)
(30 mM)-treated platelets (Fig. 1A). Incubation of platelets with
different concentrations of aspirin (2, 5 and 10 mM) was
associated with significant decrements in Dym (by 25%, 61%
and 93%, respectively) as compared to control (Fig. 1A).
Externalization of PS, an anionic phospholipid, from the inner
leaflet to outer layer of cell membrane is an invariable feature in
the apoptotic process [37,49]. PE-annexin V binding to cell
surface was studied as a measure of cells undergoing apoptosis. As
expected, surface membrane was found to be significantly
enriched with PS in thrombin-stimulated platelets as compared
to the resting cells. Remarkably, pretreatment of platelets with
increasing concentrations of aspirin (2, 5 and 10 mM) resulted in
dramatic increase (by 1.69-, 7- and 11-folds, respectively) in
annexin V binding as compared to the untreated (control) cells,
indicative of induction of apoptosis-like changes upon aspirin
treatment (Fig. 1B). Salicylic acid (10 mM) did not elicit increment
in annexin V binding, which indicated that aspirin caused PS
exposure by acetylation-dependent mechanism. To rule out the
possibility of platelet activation in response to different dosages of
aspirin, we examined surface expression of P-selectin, a marker for
platelet activation, in aspirin-treated platelets. Aspirin had no
effect on surface level of P-selectin, which was found to be
significantly elevated on surface membrane in thrombin-stimulat-
ed platelets (Figure S1).
As apoptosis is known to be associated with cellular reactive
oxygen species (ROS) generation [50], we sought to determine
whether aspirin induced ROS production in platelets. Using the
cell-permeable dye 29,79-dichlorofluorescein diacetate
(H2DCFDA), intracellular ROS was found to be significantly
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Figure 1. Study of apoptosis-like features in platelets following aspirin treatment. Mitochondrial transmembrane potential (red/green
ratio) (A), PS exposure (PE-annexin V binding) (B) and ROS generation (C) were studied in control platelets, as well as in cells pre-treated with aspirin
as indicated. In (A), CCCP (mitochondrial protonophore) has been employed as the positive control. Data are representative of five different
experiments and expressed as mean6SD. (*p,0.05 as compared to ethanol-pretreated resting platelets).
doi:10.1371/journal.pone.0105049.g001
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enhanced (by 1.96-, 6- and 8- folds) in platelets treated with 2, 5
and 10 mM of aspirin, respectively (Fig. 1C).
Early in the process of apoptosis Bax, the pro-apoptotic member
of Bcl-2 family, is known to undergo conformational change,
followed by translocation to the mitochondrial membrane [51].
We evaluated level of conformationally-changed active Bax in
aspirin pre-treated platelets using an antibody that specifically
recognizes Bax in its conformationally altered state (clone 6A7).
Exposure of platelets to aspirin in increasing concentrations (2, 5
and 10 mM) resulted in progressive increments in level of
conformationally active Bax (by 2-, 6- and 11- folds, respectively)
(Fig. 2A & B). BH3-mimetic ABT737 and specific proteasome
inhibitors like epoxomicin (1 mM), PSI (20 mM) and bortezomib
(25 mM) were used as a positive control, which induced significant
Bax activation in platelets (Fig. 2A & B).
The pro-apoptotic members of Bcl-2 family induce release of
mitochondrial cytochrome c into cytosol, which eventually leads to
caspase-3 activation through constitution of apoptosome complex
with Apaf-1 and caspase-9 [48]. As reported earlier [46], ABT737
induced significant activation of caspase-3 in platelets (Fig. 2C). A
concentration-dependent upregulation in caspase-3 activity (by 2-,
2.8- and 3- folds) (Fig. 2C) was observed in platelets exposed to
increasing doses of aspirin (2, 5 and 10 mM, respectively).
Proteasome is involved in the degradation of many short-lived
proteins that are required for cell survival. We have recently
demonstrated a central role of proteasome in delimiting platelet
life span through constitutive elimination of the conformationally
active Bax and inducing apoptosis-like changes in platelets [37]. In
order to explore the effect of aspirin on proteasome in human
platelets, we analyzed proteasomal peptidase activity in presence
of different concentrations of aspirin. We found a concentration-
dependent attenuation (by 15%, 44% and 61%) in proteasome
function in human platelets pre-treated with aspirin (2, 5 and
10 mM, respectively) (Fig. 2D). Aspirin treatment did not induce
any change in the total protein content in platelets.
Aspirin leads to decreased platelet life span
Platelet life span is determined by opposing activities of anti-
and pro-apoptotic Bcl-2 family proteins [46]. As proteasomal
activity in tumor cells influences cellular level of these proteins and
aspirin attenuated proteasome function in platelets (our earlier
figure), we investigated if aspirin can regulate platelet lifespan in
vivo in a rodent model. Consistent with earlier findings [30,31]
oral administration of aspirin to mice led to significant lowering in
platelet count by 18% and 32% (on 7th and 15th day, respectively,
at 10 mg/kg/day) and 28% and 48% (on 7th and 15th day,
respectively, at 15 mg/kg/day) (n = 5) (Fig. 3A). When adminis-
tered intravenously in tail vein in mice, 50 and 75 mg/kg of
aspirin decreased platelet count by 50% and 72%, respectively,
reflective of aspirin-induced decrease in platelet count (data not
shown).
Reduction in platelet count could either be due to increase in
platelet clearance or decreased platelet production. In order to
study former possibility we conjugated mice platelets with biotin
by intravenous administration of NHS-biotin and tracked the
labeled platelets ex vivo by incubating cells with PE-streptavidin
[44]. Consistent with earlier observation by Berger et al. (1998),
platelet half-life (t1/2= clearance of 50% biotin-conjugated plate-
lets) was found to be 80 h in control mice, which dropped
significantly to 65 h and 54 h, respectively, in mice administered
orally with aspirin at 10 and 15 mg/kg/day for 4 days (Fig. 3B).
Intravenous administration of 50 and 75 mg/kg of aspirin to the
tail vein of mice decreased half life of platelets by 21 and 37 h,
respectively (data not shown). Salicylic acid (75 mg/kg) did not
affect the platelet life span, suggesting that aspirin lowered platelet
life span via acetylation-dependent mechanism.
Aspirin enhances uptake of platelets by macrophages
Platelets undergoing apoptosis-like changes are known to be
removed by phagocytes in the reticulo-endothelial system [52].
Hence, we evaluated macrophage-assisted clearance of platelets
following aspirin treatment. Calcein-stained platelets, either
pretreated with aspirin (5 mM) or ethanol (vehicle), were
incubated with a monolayer of autologous monocyte-derived
adherent human macrophages for 45 min. The phagocyte
monolayer was next washed free of non-interacting platelets, and
subjected to flow cytometry as well as epifluorescence microscopy
to examine phagocytic uptake of platelets by macrophages.
Macrophages were gated and analyzed by flow cytometry for
fluorescence signal (FL1). The cells exhibited significantly higher
calcein fluorescence following incubation with aspirin-treated
fluorescently labeled platelets, which was reflective of enhanced
phagocytic uptake of these platelets (Fig. 3C). This finding was
further corroborated from epifluorescence microscopy of macro-
phages. Significantly higher mean fluorescence intensity (per high
power field) was found to be associated with macrophages co-
incubated with aspirin-treated platelets than the control cells,
which reflected facilitated phagocytic uptake of platelets upon
exposure to aspirin (Fig. 3D). In different experiment, platelets
from mice administered orally with aspirin (10 mg/kg/day for 7
days) were incubated with macrophages obtained from the same
animals. Cells from experimental mice exhibited significantly
higher calcein fluorescence than the control counterparts (data not
shown), which was reflective of enhanced phagocytic uptake of
these cells.
Discussion
Aspirin is one of the most widely used medications worldwide,
with more than 100 billion tablets consumed each year [53].
Aspirin is extensively used under clinical settings as an anti-
inflammatory drug and for prevention of thrombus formation/
propagation in myocardial infarction as well as stroke by inhibition
of platelet COX-1 activity. Apart from above functions, aspirin
and other NSAIDs also reportedly exhibit antiproliferative effect.
In this study we have investigated apoptosis-like changes in human
platelets elicited by aspirin and explored its effect on murine
platelet lifespan in vivo.
Here we found that, platelets exhibited features of apoptosis
following aspirin treatment, which included drop in mitochondrial
transmembrane potential, enhanced surface exposure of PS, rise in
cytosolic ROS and activation of caspase-3. The pro-apoptotic Bcl-
2 family protein Bax and Bax-specific mRNA are known to be
abundantly expressed in platelets [54,55]. Aspirin treatment
provoked significantly higher expression of conformationally active
Bax in platelets compared to their control (untreated) counter-
parts. Bax being a known substrate of proteasome [56,57] we next
examined effect of aspirin on proteasomal peptidase activity in
order to understand mechanistic underpinning of aspirin effects on
platelets. The drug was found to elicit concentration-dependent
attenuation in proteasomal function in human platelets (Fig. 2D),
which was in line with an earlier study on murine Neuro 2a cells
[29]. However, above observations did not formally establish a link
between proteasome inhibition and Bax activity. A limitation of
this study is high dose of aspirin administered in mice. Although
effective therapeutic dosage of aspirin against coronary artery
disorders is lower than that employed in this study, drug regime
against rheumatoid arthritis [9] and other systemic inflammatory
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diseases is higher by 5–10 fold, which is fairly comparable with
aspirin orally administered in mice in our study. Salicylic acid
(10 mM) did not evoke any apoptotic response, which indicated
that effect of aspirin could be due to acetylation-dependent
process.
We have recently shown that, proteasome plays critical role in
platelet survival through constitutive elimination of the conforma-
tionally active Bax [37]. As aspirin inhibited proteasome activity in
human platelets, we next asked whether the drug would adversely
affect platelet life span in an in vivo rodent model. Administration
of mice with aspirin led to thrombocytopenia. This was associated
with significant reduction in half-life of circulating platelets,
indicative of enhanced rate of platelet clearance in aspirin-
administered mice. Consistent with this, aspirin-treated human
platelets were found to be phagocytosed more efficiently by
macrophages, as demonstrated in vitro by flow cytometry as well
as epifluorescence microscopy
Figure 2. Study of proteosome and caspase-3 activities in aspirin-treated platelets (A), Western blots showing expression level of
active Bax in platelets pretreated with ethanol, aspirin, ABT737, epoxomicin, PSI and bortezomib, as indicated (upper panel)
normalized against b-actin (lower panel). (B), Quantitative representation of active Bax levels in platelet whole cell lysates determined by
densitometry of Western blots. (C), caspase-3 activity from the extent of cleavage of fluorigenic substrate AC-DEVD-AMC. (D), Assay of proteasome
enzymatic activity in platelets pretreated with ethanol, PSI (proteasome inhibitor) (10 mM) and aspirin. Data are representative of five different
experiments and expressed as mean6SD. (*p,0.05 as compared to ethanol-pretreated resting platelets).
doi:10.1371/journal.pone.0105049.g002
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Figure 3. Aspirin affects lifespan and phagocytic uptake of platelets (A), Platelet count in control as well as aspirin-administered
mice on different days. (B), Proportion of biotinylated platelets (%) in peripheral blood sample drawn from ethanol (vehicle) or aspirin (10 and
15 mg/kg) pre-administered mice 0, 24, 48, 72, and 96 h after administration of NHS-biotin. t1/2 (h) represents platelet half-life in hours. (C) and (D),
phagocytic uptake of platelets by autologous macrophages. Flow cytometry (C) and epifluorescence microscopy (D) of macrophages co-incubated
with calcein-labeled platelets pretreated either with aspirin (5 mM) or ethanol (control). Scale bars, 10 mm. Data are representative of five different
experiments.
doi:10.1371/journal.pone.0105049.g003
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To summarize, we have shown that aspirin elicits apoptosis-like
changes in human platelets in vitro and delimits platelet life span
in murine model, which was associated with proteasomal
inhibition and increased expression of conformationally active
Bax. Our observations support the contention that, platelets
should not be collected from donors under NSAID cover for
purpose of transfusion. A recent report has implicated platelets
with cancer cell proliferation [58] and aspirin has been directly
linked to prevention of cancer [59]. Thus, the observed drop in
longevity of aspirinized platelets suggests a novel mechanistic
insight of therapeutic benefit of this drug in cancer management.
Aspirin is widely used as an anti-inflammatory drug against
rheumatoid arthritis and towards prevention of occlusive platelet
thrombi in coronary as well as cerebral thrombotic events
including myocardial infarction. Therefore, observations from this
study provide cautionary framework to critically re-evaluate
therapeutic dosage regime of aspirin especially against systemic
inflammatory ailments though it is a relatively safe drug in general
clinical practice.
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